Unknown

Dataset Information

Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.


ABSTRACT: Since the year 2000, tremendous progress has been made in the understanding of castration-resistant prostate cancer (crpc), a disease state now recognized to retain androgen receptor (ar)-dependency in most cases. That understanding led to the rational design of novel therapeutic agents targeting hormonal pathways in metastatic crpc. Two new drugs-the CYP17 inhibitor abiraterone acetate and the potent ar antagonist enzalutamide-were recently shown to prolong overall survival after chemotherapy treatment in patients with metastatic disease, with the former agent also demonstrating impressive activity in the pre-chemotherapy setting. Other new drugs targeting the ar-as well as drugs targeting heat shock proteins that protect cytoplasmic ar from degradation-are currently undergoing clinical d

SUBMITTER: Leibowitz-Amit R 

PROVIDER: S-EPMC3553559 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature